Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.140 +0.130 (+4.32%)
Streaming Delayed Price Updated: 1:30 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
The companies hope to cure diseases of the liver, muscle and central nervous system. 
Via Investor's Business Daily
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
Analyst Ratings For Editas Medicine
Within the last quarter, Editas Medicine (NASDAQ:EDIT) has observed the fo... 
Via Benzinga
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. 
Via InvestorPlace
NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR). 
Via InvestorPlace
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937. 
Via InvestorPlace
EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today
After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading. 
Via InvestorPlace
22 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose... 
Via Benzinga
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
EDIT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Why Editas Medicine Stock Is Jumping Today
The gene-editing biotech company provided its Q3 update. 
Via The Motley Fool
Should You Scoop Up Shares of This Promising Biotech on the Dip?
This gene-editing specialist could still be an excellent long-term play. 
Via The Motley Fool
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful
EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
What's Hot in the Stock Market?
We've got a look at Merck and Amazon and Warby Parker and more. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
3 Spooky Healthcare Stocks I Would Avoid in October
Investors craving treats should look elsewhere this month. 
Via The Motley Fool
Editas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal
One of the leading CRISPR stock is under pressure on underwhelming data. 
Via Investor's Business Daily
EDIT Stock Is Plunging 20%. Here’s the Gene-Editing News Dragging It Down.
Today, investors in Editas Medicine and EDIT stock are pricing in some clinical trial results that are being viewed negatively by the market. 
Via InvestorPlace
52 Biggest Movers From Yesterday
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share... 
Via Benzinga
PreMarket Prep Stock Of The Day: Editas Medicine
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana... 
Via Benzinga
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber... 
Via Benzinga
Why Shares of Editas Medicine Are Lower This Morning
Incomplete data is disappointing investors after a long wait. 
Via The Motley Fool
Editas Medicine Stock Plunges As CRISPR Gene-Editing Drug Fails To Impress
Editas is working on a treatment for a blindness-causing genetic disorder. 
Via Investor's Business Daily
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.